Taking medication designed for bipolar disorder when you do not actually have the condition exposes you to the drugs’ full range of side effects without the psychiatric benefit those drugs are meant to provide. Bipolar medications fall into several classes, including lithium, anticonvulsant mood stabilizers, and atypical antipsychotics, and each carries distinct risks for someone whose brain chemistry does not need the correction. The situation is more common than most people realize, partly because bipolar disorder is frequently misdiagnosed and partly because many of these drugs are prescribed off-label for conditions like insomnia, anxiety, and treatment-resistant depression.
Why Someone Might End Up on Bipolar Medication Without Having Bipolar Disorder
Bipolar disorder is one of the most commonly misdiagnosed psychiatric conditions. A person presenting during a depressive episode can easily be diagnosed with major depression instead, and the reverse also happens: someone with recurrent depression, borderline personality disorder, or ADHD may receive an incorrect bipolar diagnosis and be started on mood stabilizers or antipsychotics they do not need.1PubMed Central. Misdiagnosis of bipolar disorder Lapses in history-taking, overlapping symptoms with other conditions, and the limitations of current diagnostic criteria all contribute to the problem.
There is also a large and growing category of intentional off-label use. Quetiapine, an atypical antipsychotic approved for bipolar disorder and schizophrenia, is routinely prescribed at low doses for insomnia and anxiety in people who have neither condition. Lithium, despite lacking an FDA indication for augmenting antidepressants, has been prescribed alongside them for decades in people with plain major depression who are not responding to standard treatment.2Mental Health Clinician. Lithium as augmentation for major depressive disorder Valproate and lamotrigine are used for seizure disorders, migraine prevention, and neuropathic pain. In these cases the prescriber knows the patient is not bipolar, but the patient may not fully understand that the drug they are taking was originally developed for a different purpose, or that the risk profile changes when the underlying condition is absent.
What Lithium Does to a Non-Bipolar Brain
Lithium is the oldest mood stabilizer in psychiatry and remains a first-line treatment for bipolar disorder. In someone who is bipolar, it smooths out the peaks and valleys of mood cycling. In someone who is not, the picture is less clear-cut and not especially pleasant.
A double-blind crossover study gave lithium to healthy volunteers for a month at therapeutic blood levels. Rather than producing emotional stability, lithium lowered average mood ratings on self-report scales, and the researchers attributed this to lithium-induced dysphoria, a vague, low-grade unpleasantness. Mood variability did not significantly decrease. The study also found huge differences between individuals: some volunteers felt noticeably worse, while a few actually experienced an opposite, mildly positive effect.3PubMed. The effects of lithium carbonate on healthy volunteers: mood stabilization? Memory and reaction time did not change in that particular study, though longer-term research paints a less reassuring picture of cognitive effects.
At the cellular level, lithium’s mechanism differs depending on whether the person’s neurobiology is “broken” in the way bipolar disorder breaks it. A study comparing bipolar patients and healthy subjects found that two weeks of lithium treatment changed protein signaling activity in blood platelets of the bipolar group but not in the healthy group, suggesting that lithium’s therapeutic action engages pathways that are dysregulated in bipolar disorder and largely leaves normal pathways alone.4PubMed. Differential effects of lithium on platelet protein phosphorylation in bipolar patients and healthy subjects The side effects, however, do not discriminate. Lithium narrows the gap between a therapeutic dose and a toxic one, meaning anyone taking it faces risks of thyroid suppression, kidney stress, tremor, and weight gain regardless of diagnosis.
Anticonvulsant Mood Stabilizers and Their Physical Toll
Valproate (sold as Depakote and other brand names) and lamotrigine are anticonvulsants that double as mood stabilizers. If you are taking one of these for a condition other than bipolar disorder, or because of a misdiagnosis, the drug still carries the same physical risks it would for anyone.
Valproate’s most serious rare side effect is liver damage. A review of reported cases found that the characteristic liver injury is a specific type of fatty liver change, and it tends to appear within the first six months of treatment. Younger patients taking multiple medications are at highest risk.5PubMed. Non-dose-related side effects of valproate More commonly, valproate causes weight gain, hair thinning, and gastrointestinal problems. In women of childbearing age, it is associated with polycystic ovary syndrome and carries one of the highest teratogenic risks of any psychiatric medication. These consequences land equally on someone taking it for bipolar disorder and someone taking it for a misdiagnosed mood condition or off-label for migraines.
Lamotrigine is generally better tolerated and does not cause the metabolic disruption valproate does. Its primary risk is a skin rash that, in rare cases, can progress to a severe and life-threatening allergic reaction. A retrospective study in adolescents confirmed that lamotrigine had a relatively low incidence of serious rash in that population, though close monitoring during dose titration remains standard practice for anyone starting the drug.6PubMed Central. Rash in Psychiatric and Nonpsychiatric Adolescent Patients Receiving Lamotrigine in Korea: A Retrospective Cohort Study
Atypical Antipsychotics and Metabolic Risk
Atypical antipsychotics like quetiapine, olanzapine, and risperidone are probably the bipolar medications most commonly taken by people who are not bipolar, because they are so widely prescribed off-label. Quetiapine at low doses has become a popular sleep aid, and olanzapine is sometimes used for anxiety or agitation. The metabolic consequences of these drugs are well documented and do not care why you are taking them.
A comparison study found that patients on olanzapine had significant increases in both body weight and blood glucose over 90 days. Blood glucose levels in the olanzapine group rose from an average of about 123 mg/dL at baseline to roughly 167 mg/dL after three months.7PubMed Central. Comparison of risperidone, olanzapine and quetiapine: effects on body weight, serum blood glucose and prolactin That kind of jump pushes many people from normal blood sugar into a pre-diabetic range, even over a relatively short period. Risperidone, by contrast, tends to raise prolactin levels more than the others, which introduces a different set of problems discussed below.
In children and adolescents, the metabolic impact is even more pronounced. Up to 60 percent of young patients on antipsychotics experience negative metabolic effects, including rapid weight gain, central obesity, insulin resistance, and abnormal cholesterol levels.8PubMed Central. The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children Because antipsychotics are often prescribed chronically starting in childhood, the cardiometabolic risk accumulates over years. Research has also linked these drugs to changes in gut bacteria in young people, which may partly explain why children gain weight so rapidly on them.9PubMed Central. The effects of antipsychotic medications on microbiome and weight gain in children and adolescents
Emotional Blunting and the Feeling of Flatness
One of the most common complaints from people on bipolar medications, whether correctly diagnosed or not, is a sense of emotional flattening. The highs are gone, but so are many of the normal positive feelings that make life enjoyable. For someone who is bipolar, this trade-off may be worth it to avoid destructive manic episodes. For someone who is not, the trade-off is pure loss.
The mechanism behind this blunting is fairly straightforward with antipsychotics: they block dopamine receptors, and dopamine is involved in motivation, pleasure, and reward. An experimental study gave the antipsychotic amisulpride to healthy volunteers and found that even partial dopamine blockade reduced how positively people rated pleasant images and lowered their physical arousal responses to those stimuli.10PubMed. Does partial blockade of dopamine D2 receptors with Amisulpride cause anhedonia? An experimental study in healthy volunteers The effect was especially pronounced for stimuli that would normally feel good. In other words, the drug did not make everything feel bad; it selectively muted positive experiences. For someone without a condition that requires dopamine suppression, the result is a world that feels duller than it should.
Lithium produces a similar but less targeted form of blunting. As the healthy volunteer study described earlier found, average mood dipped on lithium, and some people experienced outright dysphoria. The experience is sometimes described as feeling like you are watching your own life through glass: present but not fully engaged.
Hormonal and Reproductive Effects
Antipsychotic medications frequently cause elevated prolactin levels by blocking dopamine receptors in the pituitary gland. Dopamine normally keeps prolactin in check, and when that brake is removed, prolactin levels can climb significantly. The clinical consequences include menstrual irregularities, missed periods, abnormal breast milk production, sexual dysfunction, and, in men, breast tissue growth. Over the long term, elevated prolactin has been linked to reduced bone density and increased osteoporosis risk.11PubMed Central. Hyperprolactinaemia caused by antipsychotic drugs
Among the commonly used atypical antipsychotics, risperidone is the worst offender for prolactin elevation.7PubMed Central. Comparison of risperidone, olanzapine and quetiapine: effects on body weight, serum blood glucose and prolactin Quetiapine tends to have less effect on prolactin, which is part of why it has become the go-to off-label antipsychotic. But “less” is not “none,” and a person taking quetiapine for insomnia may still develop hormonal side effects they were never warned to watch for.
Tardive Dyskinesia from Antipsychotics
Tardive dyskinesia is a movement disorder, usually involving involuntary repetitive movements of the face, tongue, and jaw, that can develop after prolonged use of antipsychotic medications. It is potentially irreversible in some patients. When atypical antipsychotics replaced older drugs, many clinicians assumed the risk had essentially disappeared. That assumption turned out to be overly optimistic.12PubMed Central. Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations
A study of patients who received atypical antipsychotics for mood or anxiety disorders, not schizophrenia, found that about 6 percent developed tardive dyskinesia.13Journal of Affective Disorders. Tardive dyskinesia from atypical antipsychotic agents in patients with mood disorders in a clinical setting That is not a trivial number, especially when the drug is being used off-label for something like sleep or anxiety rather than a severe psychiatric condition. The longer you take an antipsychotic, the higher your cumulative risk. For someone who does not need the medication’s core benefit, that risk is hard to justify.
Cognitive Effects Over Time
People taking lithium or valproate over the long term sometimes notice that their memory is not as sharp as it used to be. A study comparing patients on either lithium or valproate with healthy controls found that both medication groups had impaired immediate verbal memory, meaning they had more trouble remembering lists of words read to them moments earlier. Other aspects of cognition were spared.14PubMed Central. Impaired verbal memory and otherwise spared cognition in remitted bipolar patients on monotherapy with lithium or valproate For someone who is bipolar and in remission, the benefit of preventing future episodes typically outweighs a modest memory trade-off. For someone who does not need the medication, a decline in verbal memory is damage with no corresponding gain.
Antipsychotics add their own cognitive layer. Sedation from quetiapine, in particular, often carries over into daytime grogginess. The drug alters sleep architecture in ways that may partly explain its early antidepressant properties, including changes that show up within just two to four days of starting treatment.15PubMed Central. Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression For people without a mood disorder who are taking quetiapine purely as a sleep aid, these architectural changes to sleep may produce a sedated but not truly restorative rest, leaving them foggy during the day.
What Happens When You Stop
One of the less intuitive risks of taking bipolar medication unnecessarily is what happens when you try to come off it. These are not drugs you can simply stop. Abrupt discontinuation of lithium, for example, dramatically shortens the time to the next mood episode in people who are bipolar, but it can also cause rebound effects in people who do not meet criteria for the disorder. A review noted that after abrupt cessation of lithium in bipolar patients, the average time to a new episode was just 1.7 months, compared to a natural cycle length of nearly a year before treatment.16PubMed Central. A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Antipsychotic withdrawal brings its own problems. Stopping suddenly can trigger insomnia, nausea, anxiety, and a rebound psychosis that can occur even in people who were never psychotic to begin with. The withdrawal pattern, involving early relapse symptoms consistent with pharmacological rebound rather than return of the underlying disease, is well documented across mood stabilizers and antipsychotics alike. For someone who was put on these medications without truly needing them, the withdrawal effects can ironically look like confirmation of the original diagnosis, trapping them in a cycle of continued prescribing.
Gradual tapering under medical supervision is essential. The rate of taper matters: hyperbolic dose reductions, where each step reduces the dose by a smaller absolute amount, appear to minimize the risk of rebound symptoms compared to the traditional approach of cutting the dose by equal fractions.
The Misdiagnosis Trap and Its Financial Cost
When someone receives a bipolar diagnosis they do not actually have, the treatment they receive is not just ineffective but actively harmful. Misdiagnosed patients with bipolar I disorder incur substantially higher healthcare costs than those correctly diagnosed. One analysis found that misdiagnosed patients had total yearly healthcare costs of about $21,200 compared to roughly $14,700 for correctly diagnosed patients, a difference of over $6,500 per year.17Journal of Affective Disorders. The real-world health resource use and costs of misdiagnosing bipolar I disorder The mental-health-related portion of those costs was nearly double for misdiagnosed patients.
Another study examining treatment patterns found that misdiagnosed bipolar patients received more antidepressants and fewer mood stabilizers or antipsychotics than correctly diagnosed ones, essentially getting treatment aimed at the wrong condition while also being exposed to antidepressant-related risks.18Journal of Clinical Psychiatry. Misdiagnosed patients with bipolar disorder: Comorbidities, treatment patterns, and direct treatment costs This is worth understanding from the reverse angle too: people misdiagnosed as bipolar when they actually have depression may be taken off antidepressants that were helping and put on mood stabilizers that do nothing for their actual condition, while still accumulating side effects.
When Antidepressants Given to the Wrong Person Trigger Mania
The flip side of the misdiagnosis problem deserves attention. While this article focuses on what happens when non-bipolar people take bipolar drugs, the opposite scenario, a truly bipolar person misdiagnosed with plain depression and given antidepressants, carries its own specific danger. A large retrospective study found that prior antidepressant use was associated with a significantly increased rate of new mania or bipolar diagnoses, with selective serotonin reuptake inhibitors and venlafaxine both carrying elevated risk.19PubMed Central. Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study
This matters for the person asking “what if I’m on bipolar meds and I’m not bipolar?” because it highlights that the diagnostic confusion runs in both directions. If you suspect your diagnosis is wrong, the answer is not to stop your medication on your own and switch to something else. It is to seek a thorough re-evaluation, ideally with a psychiatrist who will take a detailed lifetime mood history, ask about family history, and consider conditions that overlap with bipolar disorder, including borderline personality disorder, ADHD, and thyroid disorders.
Borderline Personality Disorder and Overlapping Drug Use
Borderline personality disorder is one of the conditions most frequently confused with bipolar disorder, and the two are often treated with overlapping medications. Mood stabilizers and antipsychotics are sometimes prescribed for borderline personality disorder to target specific symptoms like impulsivity and emotional instability. A meta-analytic review found limited evidence supporting the use of mood stabilizers and antipsychotics for specific aspects of borderline personality disorder, though not for the condition as a whole, and most studies to date have been small.20PubMed Central. Borderline personality disorder: current drug treatments and future prospects
The distinction matters because someone with borderline personality disorder who has been incorrectly labeled bipolar may spend years on medications whose side effects are real but whose benefits for their actual condition are modest at best. Therapy, particularly dialectical behavior therapy, is the evidence-based frontline treatment for borderline personality disorder, and medication plays only a supplementary role. Getting the diagnosis right is what separates effective treatment from years of unnecessary exposure to drugs that alter weight, metabolism, hormones, and cognition.
Off-Label Quetiapine for Sleep
The most widespread example of non-bipolar people taking bipolar medication is low-dose quetiapine prescribed for insomnia. Quetiapine is intensely sedating at low doses because of its strong affinity for histamine receptors, and many prescribers reach for it when standard sleep aids have not worked. Research confirms that quetiapine alters sleep architecture, increasing total sleep time and shifting the balance of sleep stages, with effects emerging within days of starting treatment.15PubMed Central. Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression
The problem is that even at low doses, quetiapine retains its metabolic effects. Weight gain, elevated blood sugar, daytime sedation, and prolactin changes can all occur at doses far below those used for bipolar disorder or schizophrenia. And because insomnia tends to be chronic, many people end up on quetiapine for years, accumulating side effects that were never part of the bargain they thought they were making when they asked for help sleeping. If you are taking quetiapine only for sleep, it is worth having a direct conversation with your prescriber about whether the benefits still outweigh the metabolic risks, and whether alternative approaches to insomnia have been adequately explored.